Small cell lung cancer (SCLC) is a fast-growing type of lung cancer that accounts for about 10-15% of all lung cancers. Unlike non-small cell lung cancer (NSCLC), which is more common and slower-growing, SCLC is known for its aggressive nature and tendency to spread quickly to other parts of the body.
Incidence
SCLC is less common than NSCLC but is more aggressive and typically diagnosed at a later stage. It predominantly affects older adults, with the majority of cases occurring in people over 60 years old.
Risk Factors
The primary risk factor for SCLC is smoking. In fact, around 98% of individuals diagnosed with SCLC are current or former smokers. The risk increases with the number of cigarettes smoked and the duration of smoking. Other risk factors include exposure to secondhand smoke, environmental toxins like radon and asbestos, and a family history of lung cancer.
Clinical Features
SCLC often presents with symptoms related to its rapid growth and early spread to other organs. Common symptoms include:
- Persistent cough
- Shortness of breath
- Chest pain
- Unintended weight loss
- Fatigue
- Hoarseness
- Swelling in the face and neck (due to superior vena cava syndrome)
- Symptoms related to metastasis (e.g., bone pain, neurological symptoms)
Because of its aggressive nature, SCLC is often diagnosed after it has already spread beyond the lungs.
Staging
Small cell lung cancer (SCLC) is categorized into two main stages: limited stage and extensive stage. In the limited stage, the cancer is confined to one side of the chest, involving only one lung and possibly nearby lymph nodes, and can be treated within a single radiation field. This stage represents about one-third of SCLC cases and is often treated with a combination of chemotherapy and radiation. Extensive stage SCLC, on the other hand, occurs when the cancer has spread beyond the single side of the chest to other parts of the body, such as the other lung, distant lymph nodes, bones, brain, liver, or other organs. This stage is more common, accounting for about two-thirds of SCLC cases, and is typically treated with chemotherapy and sometimes immunotherapy to manage symptoms and prolong life.
Clinical Course
SCLC is known for its rapid doubling time and early dissemination. Despite initial high response rates to chemotherapy and radiation, the disease often recurs, and survival rates remain low. The median survival for LS-SCLC is about 15-20 months, with a 5-year survival rate of approximately 20-25%. For ES-SCLC, the median survival drops to 8-13 months, with a 5-year survival rate of less than 5%.
Advances in treatment of SCLC
In the early days, the standard treatment for SCLC was primarily chemotherapy, with drugs like platinum and etoposide forming the backbone of therapy. These drugs were often combined with radiation therapy for patients with limited-stage SCLC, leading to improved survival rates compared to chemotherapy alone.
One of the landmark trials in the 1980s established the efficacy of combined chemotherapy and radiotherapy for limited-stage SCLC. This approach became the standard of care and significantly increased the median survival time for patients. However, despite initial responses, the majority of patients experienced relapses within two years, and the five-year survival rate remained disappointingly low.
The early 2000s saw the introduction of targeted therapies and the exploration of novel chemotherapy combinations. However, these efforts met with limited success, as the highly aggressive nature of SCLC often outpaced the effectiveness of these treatments.
A significant breakthrough came in the form of immunotherapy. The IMpower133 study, published in 2018, was practice changing for treatment of extensive-stage SCLC (ES-SCLC). This trial demonstrated that adding the immunotherapy drug atezolizumab (Tecentriq) to the standard chemotherapy regimen significantly improved overall survival and progression-free survival compared to chemotherapy alone. This was the first major advancement in decades, leading to the approval of atezolizumab for ES-SCLC and marking a new era in the treatment of this disease.
At the 2024 ASCO Annual Meeting, the ADRIATIC trial presented groundbreaking results for the treatment of limited-stage small cell lung cancer (LS-SCLC). The trial investigated the use of durvalumab (Imfinzi), an immunotherapy drug, as a consolidation therapy following standard concurrent chemoradiation. The study found that patients treated with durvalumab had significantly better outcomes compared to those given a placebo. Specifically, the overall survival rate at three years was 56.5% for the durvalumab group versus 47.6% for the placebo group, and the progression-free survival rate at two years was 46.2% for the durvalumab group compared to 34.2% for the placebo group.
These results are highly impactful for several reasons. Firstly, they provide a new, effective treatment option for patients with LS-SCLC, who historically have had limited and less effective treatment choices. Secondly, the significant improvements in both overall survival and progression-free survival suggest that durvalumab can help control the disease for a longer period, potentially leading to better long-term outcomes and a higher chance of curing the cancer. Finally, the ADRIATIC trial’s success marks a pivotal shift in the treatment paradigm for SCLC, offering hope for improved survival and quality of life for patients suffering from this aggressive cancer
References:
Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation – OncLive
Recent Comments